Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Lp-PLA2 Inhibitor
Lp-PLA2-IN-14 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with a pIC50 of 8.4 against recombinant human Lp-PLA2. This compound demonstrates significant potential in the study of neurodegenerative diseases, such as Alzheimer’s disease, glaucoma, and age-related macular degeneration, as well as cardiovascular conditions, including atherosclerosis. Lp-PLA2-IN-14 serves as a useful tool for researchers investigating the role of Lp-PLA2 in these pathologies. -
Sphingomyelinase Inhibitor
Brinazarone is a potent inhibitor of acid lysosomal sphingomyelinase, leading to the accumulation of sphingolipids within cells and resulting in cellular lipidosis. This compound enhances the cytotoxicity of specific immunotherapeutic agents, such as anti-Thy 1.2 AT15E RTA-IT on T2 cells and anti-CD5 T101 on CEM cells. Brinazarone is valuable for research applications involving sphingolipid metabolism and cancer immunotherapy studies. -
Lp-PLA2 Inhibitor
SB-435495 ditartrate is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), demonstrating a remarkable IC50 of 0.06 nM. This compound functions as a reversible, non-covalent inhibitor and is suitable for oral administration. Its inhibition of Lp-PLA2 has significant implications for research in cardiovascular diseases and inflammatory processes, making it a valuable tool for investigating pathophysiological roles and therapeutic interventions in related conditions. -
sPLA2 Inhibitor
Me-Indoxam is a potent inhibitor of secreted phospholipase A2 (sPLA2) that exhibits cell-impermeable characteristics. This compound effectively binds to the active site of sPLA2, disrupting its enzymatic function. Me-Indoxam is valuable in research applications focused on inflammation, cell signaling, and lipid metabolism, providing insights into the role of sPLA2 in various biological processes. -
PTDSS1 Inhibitor
DS07551382 is a selective inhibitor of phosphatidylserine synthase 1 (PTDSS1), effectively disrupting the intracellular synthesis of phosphatidylserine. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology. Its ability to modulate phosphatidylserine levels can provide insights into various signaling pathways involved in tumor progression and may aid in the development of novel therapeutic strategies. -
cPLA2α Inhibitor Derivative
cPLA2α-IN-derivative 1 is an inactive alcohol derivative designed to target cytosolic phospholipase A2α (cPLA2α). Although it exhibits no inhibition activity, it serves as a useful reference compound in structure-activity relationship studies. This reagent can be utilized in research focused on elucidating the role of cPLA2α in lipid metabolism and inflammatory responses. -
Phospholipase Inhibitor
A4333 is a biotinylated inhibitor of Phospholipase D1 (PLD1), selectively targeting this enzyme while sparing PLD2. This compound is significant in cancer research, demonstrating potent antitumor activity. Its specificity for PLD1 makes A4333 a valuable tool for elucidating the role of phospholipase signaling in tumor biology and potential therapeutic applications. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-16 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), a key enzyme implicated in inflammatory processes. This compound demonstrates potent inhibition of Lp-PLA2 activity, making it a valuable tool for investigating its role in neurodegenerative diseases, such as Alzheimer's disease. Its application in biochemical research supports studies focused on inflammation-related pathways and potential therapeutic targets. -
PLA2 Inhibitor
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) functions primarily as a phospholipase A2 (PLA2) inhibitor, exhibiting selective inhibition against both P388D1 cell PLA2 (IC50 = 16 µM) and snake venom PLA2 (IC50 = 14 µM). As a non-metabolizable analog of arachidonic acid, DEDA serves as a valuable tool in biochemical studies related to PLA2 activity. Its unique properties make it suitable for researching inflammatory processes and signal transduction pathways modulated by phospholipid metabolism. -
Phospholipase A2 Inhibitor
Cinatrin A is a potent inhibitor of phospholipase A2, an enzyme involved in the hydrolysis of phospholipids, leading to the generation of inflammatory mediators. This compound exhibits significant anti-inflammatory properties and is valuable for research applications focused on inflammation, pain modulation, and related signaling pathways. Its mechanism of action makes it a valuable tool for studying phospholipid metabolism and the implications of phospholipase A2 in various diseases. -
Phospholipase Inhibitor
(R)-N-(1-Hydroxypropan-2-yl)palmitamide serves as a substrate analog inhibitor targeting phospholipase A2. This compound exhibits significant inhibition of enzymatic activity, making it valuable for research related to inflammatory processes and cellular signaling. Its application in studying phospholipid metabolism and lipid mediator synthesis further enhances its utility in biochemical and pharmacological investigations. -
cPLA2α Inhibitor
AVX001 is a selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α). This compound is instrumental in the study of inflammatory processes, particularly in conditions such as psoriasis. AVX001 modulates the release of arachidonic acid, thereby influencing eicosanoid signaling pathways, and provides valuable insights into therapeutic strategies targeting inflammatory disorders. -
nSMase Inhibitor
Chlorogentisylquinone is an inhibitor of neutral sphingomyelinase (nSMase), demonstrating an IC50 value of 1.2 μM against rat meningeal cells and 7.6 μM in P388 leukemia cells. This compound is derived from the strain FOM-8108 and serves as a valuable tool for studying the role of nSMase in cellular processes. Its biological activity makes it suitable for applications in neurobiology and cancer research. -
PLA2 Inhibitor
Cinatrin C2 is a potent inhibitor of phospholipase A2 (PLA2) with an IC50 of 800 μM. This compound, sourced from Circinotrichum falcatisporum RF-641, is valuable for studying PLA2's role in various biological processes. It is applicable in research areas related to inflammation, pain mechanisms, and cellular signaling pathways. -
ASM Inhibitor
ASM-IN-3 is a selective inhibitor of acid sphingomyelinase (ASM) with a reported IC50 of 3.37 μM for human ASM. This compound demonstrates the ability to penetrate the blood-brain barrier and has been shown to enhance neurogenesis in the hippocampus, alleviating depression-like behaviors in Reserpine-induced rat models. ASM-IN-3 serves as a valuable tool for research in neurobiology and the treatment of mood disorders. -
PLA2 Inhibitor
Cinatrin C3 is a selective phospholipase A2 (PLA2) inhibitor, exhibiting an IC50 value of 70 μM. This compound is derived from the marine fungus Circinotrichum falcatisporum RF-641. Cinatrin C3 is utilized in research to explore the functional roles of PLA2 in various biological processes, including inflammation and cellular signaling pathways. Its inhibitory properties make it a valuable tool for studying the mechanistic functions of PLA2 in pathophysiological contexts. -
PLA2 Inhibitor
Cinatrin C1 is a selective phospholipase A2 (PLA2) inhibitor derived from the fungus Circinotrichum falcatisporum RF-641. This compound exhibits significant biological activity by modulating lipid metabolism and inflammatory processes. Cinatrin C1 serves as a valuable tool in biochemical research focused on elucidating the role of PLA2 in various physiological and pathological conditions. -
FabZ Inhibitor
HpFabZ-IN-1 is an inhibitor of the FabZ enzyme, which plays a crucial role in the fatty acid synthesis pathway of Helicobacter pylori. With an IC50 value of 39.8 µM, this compound is primarily utilized in research investigating fatty acid biosynthesis and related metabolic pathways in H. pylori. Although it does not exhibit antibacterial activity, HpFabZ-IN-1 serves as an important tool for studying the molecular mechanisms underlying this pathogenic bacterium. -
PLD Inhibitor
ARF1 (2-17) is a selective inhibitor of phospholipase D (PLD) and phospholipase C-β (PLC-β), targeting both ARF-dependent and ARF-independent signaling pathways. This compound effectively inhibits GTP-γ-S-stimulated PLD activity, thereby playing a crucial role in modulating exocytosis and related cellular processes. Its application in research includes studying lipid signaling and the regulation of membrane traffic in cellular models. -
Phospholipase A2 Inhibitor
Cinatrin B is a potent inhibitor of phospholipase A2, an enzyme involved in the hydrolysis of phospholipids, leading to the release of arachidonic acid and the subsequent production of inflammatory mediators. This compound demonstrates significant biological activity in modulating inflammatory responses and has potential applications in research related to inflammation and related diseases. Its ability to selectively inhibit phospholipase A2 makes Cinatrin B a valuable tool for studying lipid metabolism and signaling pathways in various biological systems. -
Phospholipase A2 Inhibitor
Ro 31-4639 is a potent inhibitor of phospholipase A2, displaying an IC50 of 1.5 μM. This compound is valuable for studying the role of phospholipase A2 in inflammatory processes and membrane biochemistry. Its inhibitory activity makes it a critical tool in investigating pathways related to lipid metabolism and the modulation of arachidonic acid release. -
cPLA2 Inhibitor
AK106-001616 is a selective inhibitor of cytosolic phospholipase A2 (cPLA2), exhibiting a potent inhibition with an IC50 of 3.8 nmol/L. This compound effectively reduces the synthesis of pro-inflammatory mediators, including prostaglandins E2 and leukotrienes B4, in stimulated cells. AK106-001616 is valuable for research into inflammatory diseases, neuropathic pain, and pulmonary fibrosis, providing insights into the modulation of inflammatory pathways. -
Phospholipase C Inhibitor
Hispidospermidin is a selective inhibitor of phospholipase C, a key enzyme involved in various signal transduction pathways. This compound exhibits significant biological activity by modulating intracellular calcium signaling and inositol phosphate metabolism. Its potential applications in research include studying cellular signaling mechanisms and investigating diseases related to dysregulated phospholipase C activity. -
ASM Inhibitor
ARC39 is a selective inhibitor of acid sphingomyelinase (ASM), a key enzyme involved in sphingolipid metabolism. By inhibiting ASM, ARC39 modulates sphingolipid levels, which play critical roles in cellular signaling and stress responses. Its biological activity makes it a valuable tool for research related to neurodegenerative diseases, cancer, and inflammation, facilitating the exploration of sphingolipid-related pathways in various cellular contexts. -
N-SMase 2 Inhibitor
DPTIP hydrochloride is a selective inhibitor of neutral sphingomyelinase 2 (N-SMase 2), exhibiting an IC50 of 30 nM. This compound is known for its ability to penetrate the blood-brain barrier, making it a valuable tool for studying exosome-mediated cellular processes. Research applications include investigations into neurodegenerative diseases and the role of sphingosine metabolism in cellular signaling pathways. -
nSMase Inhibitor
Sphingolactone-24 is a selective and irreversible inhibitor of neutral sphingomyelinase (nSMase). This compound is significant in biological research due to its ability to modulate sphingolipid metabolism, which plays a critical role in various cellular processes. Sphingolactone-24 is particularly useful in studies related to acute lung injury, enabling researchers to explore therapeutic interventions in respiratory conditions associated with nSMase activity. -
Group IVA Cytosolic Phospholipase A2 Inhibitor
GK470 is a potent inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. This compound exhibits significant anti-inflammatory activity by inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes, with an IC50 of 0.6 μM. GK470 demonstrates comparable anti-inflammatory effects to conventional therapies in models of arthritis and effectively reduces plasma PGE2 levels, making it a valuable tool for researching inflammatory pathways and potential therapeutic interventions. -
MAO-B Inhibitor
MAO-B-IN-10 is a selective monoamine oxidase B (MAO-B) inhibitor with a potent IC50 of 5.3 μM. It effectively inhibits and disaggregates amyloid β (Aβ) aggregation, achieving 58.2% inhibition and 43.3% disaggregation of self-mediated Aβ. This compound is valuable for research related to Alzheimer's disease, offering insights into the modulation of Aβ aggregation in neurodegenerative processes. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
AChE/MAO-B Inhibitor
AChE/MAO-B-IN-9 is a selective, reversible, non-competitive inhibitor of acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.156 μM against electric eel AChE. This compound effectively inhibits the formation of Aβ40/42 fibrils, promotes the depolymerization of Aβ fibrils, and suppresses Tau protein fibril formation. Additionally, AChE/MAO-B-IN-9 demonstrates antioxidant and neuroprotective properties, while alleviating memory deficits induced by scopolamine in murine models. This reagent is valuable for research related to Alzheimer’s disease. -
BuChE inhibitor
Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of butyrylcholinesterase (BuChE), functioning through irreversible inhibition. This compound is primarily utilized in research to investigate the mechanisms of BuChE and the resulting effects on acetylcholine metabolism. Iso-OMPA has been shown to enhance soman toxicity in rat models, linked to the inhibition of plasma carboxylesterase (CarbE), making it a valuable tool in studies of nerve agent effects and cholinergic signaling. -
CYP2D6/AChE Inhibitor
Rhodiosin is a dual inhibitor of CYP2D6 and acetylcholinesterase (AChE), extracted from the root of Rhodiola rosea. It exhibits an IC50 value of 0.761 μM for CYP2D6 and a Ki of 0.769 μM. This compound demonstrates notable antioxidant and neuroprotective properties, contributing to the regulation of the HIF-1α signaling pathway, which is vital for central nervous system protection. Rhodiosin serves as a valuable tool for research in neuropharmacology and metabolic studies. -
Dual MAO/AChE Inhibitor
Ladostigil hemitartrate is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), with established IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound is capable of crossing the blood-brain barrier and exhibits neuroprotective, antioxidant, and anti-inflammatory properties. Ladostigil hemitartrate is relevant for research into neurological disorders, including depression and Alzheimer's disease. Additionally, it functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO/AChE Inhibitor
Ladostigil hydrochloride is a potent dual inhibitor of acetylcholinesterase (AChE) and monoamine oxidase-B (MAO-B), exhibiting IC50 values of 37.1 µM and 31.8 µM, respectively. This compound demonstrates neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research related to depression and Alzheimer's disease. Additionally, Ladostigil hydrochloride functions as a click chemistry reagent, featuring an alkyne group that can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating diverse chemical applications. -
Dual MAO and AChE Inhibitor
Ladostigil is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), demonstrating IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound exhibits neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research in conditions such as depression and Alzheimer's disease. Additionally, Ladostigil features an alkyne functional group, enabling it to serve as a click chemistry reagent through copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO Inhibitor
ASS234 is a potent monoamine oxidase (MAO) inhibitor, targeting MAO-A and MAO-B with IC50 values of 5.2 nM and 43 nM, respectively. In addition to its primary activity, ASS234 also exhibits inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 350 nM and 460 nM, respectively. This compound can be utilized in research related to neurodegenerative diseases, mood disorders, and cholinergic signaling pathways. -
AChE-MAO B Inhibitor
Dual AChE-MAO B-IN-2 is a powerful inhibitor of both acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), exhibiting IC50 values of 0.12 µM and 0.01 µM, respectively. This dual inhibition profile suggests its significant potential in the study and development of therapeutic strategies for Alzheimer's disease. Researchers can utilize Dual AChE-MAO B-IN-2 to explore mechanisms related to cholinergic dysfunction and oxidative stress in neurodegenerative conditions. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE/BuChE/MAO-B Inhibitor
AChE/BuChE/MAO-B-IN-1 is a potent inhibitor of human acetylcholinesterase (hAChE), butyrylcholinesterase (hBuChE), and monoamine oxidase-B (hMAO-B), with IC50 values of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. This compound also demonstrates a high affinity for σ1 and σ2 receptors, with Ki values of 42.8 nM and 191 nM, respectively. AChE/BuChE/MAO-B-IN-1 is potentially useful in research focused on Alzheimer's disease and related neurological disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-1 is a reversible inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B), exhibiting IC50 values of 7.31 μM, 0.56 μM, and 26.1 μM, respectively. This compound effectively crosses the blood-brain barrier and demonstrates neuroprotective properties while maintaining a lack of cytotoxicity. Its multifaceted inhibition profile makes it a valuable tool for research on neurodegenerative diseases and associated pathways. -
Dual MAO-AChE Inhibitor
MAO-A/B-IN-3 is a dual inhibitor targeting both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), as well as acetylcholinesterase (AChE). With IC50 values of 67 nM for MAO-A, 29 nM for MAO-B, and 1370 nM for AChE, this compound demonstrates substantial multi-target efficacy. MAO-A/B-IN-3 modifies key binding sites to enhance its inhibitory activity against MAO enzymes while reducing the impact on AChE. This reagent is particularly relevant for research focused on neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-20 is a potent acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 397.32 nM and a Ki value of 335.76 nM. In addition to its primary target, AChE-IN-20 exhibits significant inhibitory activity against human carbonic anhydrases I and II, and α-glucosidase, with IC50 values of 84.14 nM, 69.24 nM, and 52.08 nM, respectively. This compound is valuable for research into neurodegenerative diseases and enzymatic regulation, providing insights into potential therapeutic strategies. -
MAO Inhibitor
Benzylhydrazine is a potent inhibitor of monoamine oxidase (MAO), targeting both brain and liver tissues. It exhibits significant inhibitory activity with pI50 values of 6.3 and 7.0 for brain and liver MAO, respectively. In vivo studies have demonstrated its efficacy in mice, with effective doses (ED50) of 6.5 μmol/kg for brain MAO and 6.2 μmol/kg for liver MAO. This compound is useful for research involving neurochemistry and metabolic studies related to neurotransmitter regulation. -
MAOA Inhibitor
Ethyl homovanillate is a selective inhibitor of monoamine oxidase A (MAOA) with an IC50 value of 8.1 μM. This compound demonstrates significant efficacy in improving depressive-like behavior, as evidenced by enhanced scores in the forced swim test in ICR mice. Ethyl homovanillate is a valuable reagent for investigating the mechanisms underlying neurological diseases, particularly Alzheimer's disease, and offers potential insights into therapeutic strategies for mood regulation. -
Monoamine Oxidase Inhibitor
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor, displaying Ki values of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. This compound exhibits notable antihypertensive and anticancer activities. Additionally, Pargyline functions as a click chemistry reagent due to its alkyne group, allowing for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. -
MAO-A Inhibitor
Clorgyline is a selective inhibitor of monoamine oxidase A (MAO-A) that is orally active and permeable to the blood-brain barrier. By inhibiting MAO-A, Clorgyline decreases the metabolism of neurotransmitters like serotonin (5-hydroxytryptamine), resulting in increased levels in the brain. This compound is particularly valuable for research applications focused on depression and neurodegenerative diseases. -
MAO-B Inhibitor
Mofegiline hydrochloride is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B), exhibiting a significant preference over monoamine oxidase A (MAO-A) with IC50 values of 3.6 nM and 680 nM, respectively. This compound also inhibits semicarbazide-sensitive amine oxidase (SSAO). Mofegiline hydrochloride is utilized in research focused on neurodegenerative disorders and the modulation of neurotransmitter levels. Its specific action on MAO-B makes it a valuable tool in studies addressing dopamine metabolism and potential therapeutic strategies for Parkinson's disease. -
MAO-B Inhibitor
Tisolagiline is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 8 nM. This compound demonstrates neuroprotective effects and possesses anti-neuroinflammatory properties, making it valuable for research in neurological disorders. Tisolagiline may be useful in studying the role of MAO-B in neurodegenerative conditions and evaluating potential therapeutic strategies for such diseases.
